T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H1 2018
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H1 2018
SUMMARY
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) pipeline Target constitutes close to 19 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Surface Glycoprotein CD4 - Pipeline Review, H1 2018, outlays comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It regulates T-cell activation. It induces the aggregation of lipid rafts. It acts as a receptor for human immunodeficiency virus-1, human Herpes virus 7/HHV-7. It is down regulated by HIV-1 Vpu.
The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 4 molecules, respectively. Report covers products from therapy areas Infectious Disease, Immunology, Cardiovascular and Central Nervous System which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Autoimmune Disorders, Encephalitis, Graft Versus Host Disease (GVHD), Influenza A Virus, H5N1 Subtype Infections, Malaria, Myocarditis, Severe Acute Respiratory Syndrome (SARS), Simplexvirus (HSV) Infections, Smallpox, Systemic Lupus Erythematosus and West Nile Virus Infections.
Furthermore, this report also reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) pipeline Target constitutes close to 19 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Surface Glycoprotein CD4 - Pipeline Review, H1 2018, outlays comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It regulates T-cell activation. It induces the aggregation of lipid rafts. It acts as a receptor for human immunodeficiency virus-1, human Herpes virus 7/HHV-7. It is down regulated by HIV-1 Vpu.
The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 4 molecules, respectively. Report covers products from therapy areas Infectious Disease, Immunology, Cardiovascular and Central Nervous System which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Autoimmune Disorders, Encephalitis, Graft Versus Host Disease (GVHD), Influenza A Virus, H5N1 Subtype Infections, Malaria, Myocarditis, Severe Acute Respiratory Syndrome (SARS), Simplexvirus (HSV) Infections, Smallpox, Systemic Lupus Erythematosus and West Nile Virus Infections.
Furthermore, this report also reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
- The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Overview
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Companies Involved in Therapeutics Development
Biotest AG
Bristol-Myers Squibb Co
CEL-SCI Corp
Fountain Biopharma Inc
Immupharma Plc
Sanofi
TaiMed Biologics Inc
United Biomedical Inc
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles
Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit CD4 and gp120 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
forigerimod acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-48U1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAX-16H5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit CD4 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit CD4 for Immunoinflammatory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate CD4 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMB-360 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMB-365 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tregalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-421 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Products
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Discontinued Products
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Product Development Milestones
Featured News & Press Releases
Apr 30, 2018: Theratechnologies Announces that Trogarzo (Ibalizumab-Uiyk) Injection is Now Available in the U.S.
Apr 30, 2018: Theratechnologies to Present Data on Trogarzo at Bloom Burton Healthcare Investor Conference
Apr 24, 2018: Theratechnologies to Seek Regulatory Approval of Trogarzo (ibalizumab) in Europe
Apr 17, 2018: ImmuPharma announces Top line results of Lupuzor Pivotal Phase III Trial
Mar 23, 2018: ImmuPharma: Lupuzor Pivotal Phase III Study Update
Mar 15, 2018: United BioPharma received approval of the multi-nation, multi-center phase 3 IND from Thailand FDA for UB-421 in HAART substitution trial
Mar 08, 2018: Option Care Selected as the Home and Alternate Site Infusion Provider for Newly Approved Breakthrough Therapy, Trogarzo (ibalizumab-uiyk) Injection
Mar 07, 2018: New Positive Data on Trogarzo (ibalizumab-uiyk) Injection Presented at 25th Conference on Retroviruses and Opportunistic Infections
Mar 07, 2018: WuXi Biologics Congratulates TaiMed on FDA Approval for Trogarzo
Mar 06, 2018: FDA Approves New HIV Treatment for Patients who have Limited Treatment Options
Mar 06, 2018: Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1
Jan 18, 2018: ImmuPharma Announces Completion of Lupuzor Pivotal Phase III Study and Initiation of Follow Up Study
Dec 21, 2017: Last patient completes dosing in Lupuzor Pivotal Phase III Study
Nov 13, 2017: Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018
Nov 02, 2017: ImmuPharma: Update on Lupuzor Pivotal Phase III Study2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Overview
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Companies Involved in Therapeutics Development
Biotest AG
Bristol-Myers Squibb Co
CEL-SCI Corp
Fountain Biopharma Inc
Immupharma Plc
Sanofi
TaiMed Biologics Inc
United Biomedical Inc
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles
Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit CD4 and gp120 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
forigerimod acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-48U1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAX-16H5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit CD4 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit CD4 for Immunoinflammatory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate CD4 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMB-360 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMB-365 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tregalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-421 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Products
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Discontinued Products
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Product Development Milestones
Featured News & Press Releases
Apr 30, 2018: Theratechnologies Announces that Trogarzo (Ibalizumab-Uiyk) Injection is Now Available in the U.S.
Apr 30, 2018: Theratechnologies to Present Data on Trogarzo at Bloom Burton Healthcare Investor Conference
Apr 24, 2018: Theratechnologies to Seek Regulatory Approval of Trogarzo (ibalizumab) in Europe
Apr 17, 2018: ImmuPharma announces Top line results of Lupuzor Pivotal Phase III Trial
Mar 23, 2018: ImmuPharma: Lupuzor Pivotal Phase III Study Update
Mar 15, 2018: United BioPharma received approval of the multi-nation, multi-center phase 3 IND from Thailand FDA for UB-421 in HAART substitution trial
Mar 08, 2018: Option Care Selected as the Home and Alternate Site Infusion Provider for Newly Approved Breakthrough Therapy, Trogarzo (ibalizumab-uiyk) Injection
Mar 07, 2018: New Positive Data on Trogarzo (ibalizumab-uiyk) Injection Presented at 25th Conference on Retroviruses and Opportunistic Infections
Mar 07, 2018: WuXi Biologics Congratulates TaiMed on FDA Approval for Trogarzo
Mar 06, 2018: FDA Approves New HIV Treatment for Patients who have Limited Treatment Options
Mar 06, 2018: Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1
Jan 18, 2018: ImmuPharma Announces Completion of Lupuzor Pivotal Phase III Study and Initiation of Follow Up Study
Dec 21, 2017: Last patient completes dosing in Lupuzor Pivotal Phase III Study
Nov 13, 2017: Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018
Nov 02, 2017: ImmuPharma: Update on Lupuzor Pivotal Phase III Study2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Biotest AG, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by CEL-SCI Corp, H1 2018
Pipeline by Fountain Biopharma Inc, H1 2018
Pipeline by Immupharma Plc, H1 2018
Pipeline by Sanofi, H1 2018
Pipeline by TaiMed Biologics Inc, H1 2018
Pipeline by United Biomedical Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Biotest AG, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by CEL-SCI Corp, H1 2018
Pipeline by Fountain Biopharma Inc, H1 2018
Pipeline by Immupharma Plc, H1 2018
Pipeline by Sanofi, H1 2018
Pipeline by TaiMed Biologics Inc, H1 2018
Pipeline by United Biomedical Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Biotest AG
Bristol-Myers Squibb Co
CEL-SCI Corp
Fountain Biopharma Inc
Immupharma Plc
Sanofi
TaiMed Biologics Inc
United Biomedical Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Biotest AG
Bristol-Myers Squibb Co
CEL-SCI Corp
Fountain Biopharma Inc
Immupharma Plc
Sanofi
TaiMed Biologics Inc
United Biomedical Inc
